Caspase inhibitors: a review of recently patented compounds (2013-2015).

Introduction: Although many caspase inhibitors have been patented, caspase inhibitors have not entered the market due to their toxicity and poor pharmacokinetic profile.

Areas Covered: In this article, we review patents (2013-2015) for peptide and non-peptide caspase inhibitors and their compositions.

Expert Opinion: Noteworthy patents include a peptidic caspase-2 inhibitor for nasal administration and a peptidomimetic caspase-6 inhibitor that can be administered via several routes for the treatment of neurodegenerative diseases.